Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Wang, Yucai; Zhou, Shouhao; Yang, Fang; Qi, Xinyue; Wang, Xin; Guan, Xiaoxiang; Shen, Chan; Duma, Narjust; Vera Aguilera, Jesus; V. Chintakuntlawar, Ashish; A. Price, Katharine; R. Molina, Julian; C. Pagliaro, Lance; R. Hálfdánarson, Þorvarður; Grothey, Axel; N. Markovic, Svetomir; S. Nowakowski, Grzegorz; M. Ansell, Stephen; Wang, Michael

doi:10.1001/jamaoncol.2019.0393

Public

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

Published in JAMA Oncology • Apr 25, 2019

Authors:

Yucai Wang

Shouhao Zhou

Fang Yang

Abstract

IMPORTANCE: Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice. OBJECTIVE: To evaluate the incidences of treatment-relate...

Subject

Medicine

Adverse effect

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!